Functional bowel disorders - PubMed (original) (raw)
Review
Functional bowel disorders
George F Longstreth et al. Gastroenterology. 2006 Apr.
Erratum in
- Gastroenterology. 2006 Aug;131(2):688
Abstract
Employing a consensus approach, our working team critically considered the available evidence and multinational expert criticism, revised the Rome II diagnostic criteria for the functional bowel disorders, and updated diagnosis and treatment recommendations. Diagnosis of a functional bowel disorder (FBD) requires characteristic symptoms during the last 3 months and onset > or =6 months ago. Alarm symptoms suggest the possibility of structural disease, but do not necessarily negate a diagnosis of an FBD. Irritable bowel syndrome (IBS), functional bloating, functional constipation, and functional diarrhea are best identified by symptom-based approaches. Subtyping of IBS is controversial, and we suggest it be based on stool form, which can be aided by use of the Bristol Stool Form Scale. Diagnostic testing should be guided by the patient's age, primary symptom characteristics, and other clinical and laboratory features. Treatment of FBDs is based on an individualized evaluation, explanation, and reassurance. Alterations in diet, drug treatment aimed at predominant symptoms, and psychotherapy may be beneficial.
Similar articles
- Efficient diagnosis of suspected functional bowel disorders.
Gunnarsson J, Simrén M. Gunnarsson J, et al. Nat Clin Pract Gastroenterol Hepatol. 2008 Sep;5(9):498-507. doi: 10.1038/ncpgasthep1203. Nat Clin Pract Gastroenterol Hepatol. 2008. PMID: 18679389 Review. - Functional bowel disorders and functional abdominal pain.
Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Thompson WG, et al. Gut. 1999 Sep;45 Suppl 2(Suppl 2):II43-7. doi: 10.1136/gut.45.2008.ii43. Gut. 1999. PMID: 10457044 Free PMC article. Review. - Subtyping the irritable bowel syndrome by predominant bowel habit: Rome II versus Rome III.
Ersryd A, Posserud I, Abrahamsson H, Simrén M. Ersryd A, et al. Aliment Pharmacol Ther. 2007 Sep 15;26(6):953-61. doi: 10.1111/j.1365-2036.2007.03422.x. Aliment Pharmacol Ther. 2007. PMID: 17767480 - Differentiating functional constipation from constipation-predominant irritable bowel syndrome: management implications.
Talley NJ. Talley NJ. Rev Gastroenterol Disord. 2005 Winter;5(1):1-9. Rev Gastroenterol Disord. 2005. PMID: 15741927 Review.
Cited by
- Impact of Enteric Nervous Cells on Irritable Bowel Syndrome: Potential Treatment Options.
Pastras P, Aggeletopoulou I, Triantos C. Pastras P, et al. Microorganisms. 2024 Oct 9;12(10):2036. doi: 10.3390/microorganisms12102036. Microorganisms. 2024. PMID: 39458345 Free PMC article. Review. - Inflammatory Prostatitis Plus IBS-D Subtype and Correlation with Immunomodulating Agent Imbalance in Seminal Plasma: Novel Combined Treatment.
Castiglione R, Bertino G, Vicari BO, Rizzotto A, Sidoti G, D'Agati P, Salemi M, Malaguarnera G, Vicari E. Castiglione R, et al. Diseases. 2024 Oct 18;12(10):260. doi: 10.3390/diseases12100260. Diseases. 2024. PMID: 39452503 Free PMC article. - The magnitude of chronic constipation and associated factors among type 2 diabetic patients in Harar, Eastern Ethiopia.
Mogess WN, Mihretie TB, Habte ML, Feyisa TO, Areda BG, Ahmed ET, Diribsa GC, Zeleke M, Alemseged NM, Amentie E, Wodajo TB, Borushe TR. Mogess WN, et al. Clin Diabetes Endocrinol. 2024 Oct 17;10(1):33. doi: 10.1186/s40842-024-00188-3. Clin Diabetes Endocrinol. 2024. PMID: 39415289 Free PMC article. - Neuroplasticity of the white matter tracts underlying recovery of diarrhea-predominant irritable bowel syndrome following acupuncture treatment.
Li J, Ng W, Liu Y, Fang X, Wang Z, Pei L, Wei X. Li J, et al. Front Neurosci. 2024 Sep 19;18:1383041. doi: 10.3389/fnins.2024.1383041. eCollection 2024. Front Neurosci. 2024. PMID: 39364438 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical